Skip to main content
OpenTrials
Completed

NCT Number: NCT04296643

Medical Masks vs N95 Respirators for COVID-19

A randomized controlled trial in which health care workers will be randomized to either medical masks or N95 respirators when providing care to patients with COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Foothills Medical Centre, Calgary, Alberta, Canada

Loading trial locations.

About this study

A randomized controlled trial in which health care workers will be randomized to either medical masks or N95 respirators when providing medical care to patients with COVID-19. This multi-centre randomized controlled trial will assess whether medical masks are non-inferior to N95 respirators when health care workers provide care involving non-aerosol generating procedures. Health care workers will be randomized to either use of a medical mask or to a fit-tested N95 respirator when providing care for patients with febrile respiratory illness. Health care workers randomly assigned to the N95 respirator group will be instructed to use a fit-tested National Institute for Occupational Safety and Health-approved N95 respirator when providing routine care to patients with COVID-19 or suspected COVID-19. Participants will use the type of device they were allocated to, either a medical mask or an N95 respirator, for 10 weeks, however, health care workers can also use the N95 respirator at any time based on a point-of-care risk assessment. Universal masking is the policy implemented at each study site. Extended and re-use of N95 respirators will be permitted if the local situation requires it. The primary outcome is laboratory confirmed RT-PCR COVID-19 among participants.

A nasopharyngeal swab will be obtained if any one of the following symptoms or signs is present: fever (≥38 C), cough, or shortness of breath, or if 2 of the following are present: fatigue, myalgia, headache, dizziness, expectoration, sore throat, diarrhea, nausea, vomiting, abdominal pain, runny nose, altered taste or smell, conjunctivitis, or painful swallowing.

Participants that receive a COVID-19 vaccine after enrollment with efficacy of > 50% for the circulating strain will continue to be followed until 2 weeks after the first dose of the vaccine. All other participants will be followed for 10 weeks.

Self-reporting of hand hygiene and the use of external monitors, where feasible, will be used to collect basic hand hygiene data.

The sample size is 1,010 participants. This will allow 90% power at an alpha (one sided) of 0.05 and to account for participants who may not have completed 10 weeks because of COVID-19 mRNA vaccination.

Changes made to the protocol prior to May 4, 2020, which was prior to the start of enrollment:

  • Eligibility criteria expanded from nurses who provide direct patient care to health care workers that provide direct patient care.
  • Allowed extended and re-use of N95 respirators if the local situation required it.
  • Added self-reporting of hand hygiene and the use of external monitors if feasible.
  • Reduced the duration of follow up from 12 weeks to 10 weeks

Changes made on or after May 4, 2020:

  • Expanded the criteria for the requirement of swabs to detect COVID-19 by adding runny nose, altered taste or smell, and conjunctivitis and also asked for a swab for fever, cough, or shortness of breath alone OR for two of the previously listed symptoms or signs (May 19, 2020).
  • Added previously known COVID infection as an exclusion (October, 30, 2020).
  • Added receipt of a COVID-19 vaccine with efficacy of > 50% as an exclusion (October 30, 2020).
  • Allowed those participants that received a COVID-19 vaccine after enrollment with efficacy of > 50% for the circulating strain to continue to be followed until 2 weeks after the first dose of the vaccine (December 17, 2020).
  • Increased the sample size to 1,010 participants to allow 90% power at an alpha (one sided) of 0.05 and to account for participants who may not have completed 10 weeks because of COVID-19 mRNA vaccination (July 26, 2021).
  • Added wording to capture implementation since May 4th, 2020, "Where the policy of the healthcare setting has been universal use of a facemask, that is wearing a facemask at all times when in the hospital, then the facemask participants were randomized to will be used." (December 27, 2021)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Health care workers who provide direct care to patients with suspected or confirmed COVID-19 in specialized COVID-19 units and in emergency departments, medical units, pediatric units, and long-term care facilities
  • Health care workers are required to spend 60% or more of their time doing clinical work when enrolled.

Exclusion criteria

  • Unable to pass or do not have a valid fit test within the past 24 months
  • One or more high-risk comorbidities for COVID-19 (hypertension, cardiac disease, pulmonary disease, chronic kidney disease, diabetes, chronic liver disease, actively treated cancer, or immunosuppression due to illness or medications)
  • Previous laboratory confirmed clinical diagnosis of COVID-19 at the time of
  • Received 1 or more doses of a COVID-19 vaccine with greater than 50% efficacy for the circulating strain (for example, mRNA or vector-based COVID-19 vaccine against the original SARS-CoV-2 strain).
  • working in intensive care units.

Treatment and study plan

Medical Mask

Device

Medical Mask (known also as Surgical Mask)

N95 Respirator

Device

N95 respirator

Primary outcomes

  1. RT-PCR confirmed COVID-19 infection

    Time frame: 10 weeks

    Number of participants with RT-PCR confirmed COVID-19 infection

Secondary outcomes

  1. Acute respiratory illness

    Time frame: 10 weeks

    Number of participants with acute respiratory illness

  2. Absenteeism

    Time frame: 10 weeks

    Number of participants with absenteeism

  3. Lower respiratory infection

    Time frame: 10 weeks

    Number of participants with lower respiratory infection

  4. Pneumonia

    Time frame: 10 weeks

    Number of participants with pneumonia

  5. ICU admission

    Time frame: 10 weeks

    Number of participants with ICU admission

  6. Mechanical ventilation

    Time frame: 10 weeks

    Number of participants needing mechanical ventilation

  7. Death

    Time frame: 10 weeks

    Number of participants that died

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • University of Alberta

Registry information

Official study title

Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Mar 5, 2020
Registry last updated
Jan 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.